Neurocrine Biosciences Stock Fundamentals
| NBIX Stock | USD 126.59 1.32 1.03% |
Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.
At this time, Neurocrine Biosciences' Total Operating Expenses is fairly stable compared to the past year. Income Before Tax is likely to rise to about 348.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 38.9 M in 2024. Neurocrine | Select Account or Indicator |
Neurocrine Biosciences Company Return On Equity Analysis
Neurocrine Biosciences' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Neurocrine Biosciences Return On Equity | 0.16 |
Most of Neurocrine Biosciences' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Neurocrine Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Neurocrine Biosciences has a Return On Equity of 0.1635. This is 100.68% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The return on equity for all United States stocks is 152.74% lower than that of the firm.
Neurocrine Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neurocrine Biosciences's current stock value. Our valuation model uses many indicators to compare Neurocrine Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurocrine Biosciences competition to find correlations between indicators driving Neurocrine Biosciences's intrinsic value. More Info.Neurocrine Biosciences is regarded fourth in return on equity category among its peers. It is regarded second in return on asset category among its peers reporting about 0.72 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Neurocrine Biosciences is roughly 1.39 . At this time, Neurocrine Biosciences' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurocrine Biosciences' earnings, one of the primary drivers of an investment's value.Neurocrine Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.Neurocrine Biosciences is currently under evaluation in return on equity category among its peers.
Neurocrine Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurocrine Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurocrine Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Neurocrine Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 11.84 B | ||||
| Shares Outstanding | 101.25 M | ||||
| Shares Owned By Insiders | 0.99 % | ||||
| Shares Owned By Institutions | 95.61 % | ||||
| Number Of Shares Shorted | 4.24 M | ||||
| Price To Earning | 202.90 X | ||||
| Price To Book | 4.76 X | ||||
| Price To Sales | 5.71 X | ||||
| Revenue | 1.89 B | ||||
| Gross Profit | 1 B | ||||
| EBITDA | 358 M | ||||
| Net Income | 249.7 M | ||||
| Cash And Equivalents | 799.4 M | ||||
| Cash Per Share | 8.31 X | ||||
| Total Debt | 428.4 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 26.87 X | ||||
| Cash Flow From Operations | 389.9 M | ||||
| Short Ratio | 4.28 X | ||||
| Earnings Per Share | 3.71 X | ||||
| Price To Earnings To Growth | 0.30 X | ||||
| Target Price | 163.46 | ||||
| Number Of Employees | 1.7 K | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 12.82 B | ||||
| Total Asset | 3.25 B | ||||
| Retained Earnings | (157.1 M) | ||||
| Working Capital | 952.2 M | ||||
| Current Asset | 384.07 M | ||||
| Current Liabilities | 25.71 M | ||||
| Net Asset | 3.25 B |
About Neurocrine Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 263.7 M | 276.9 M | |
| Total Revenue | 1.9 B | 2 B | |
| Cost Of Revenue | 39.7 M | 38.9 M | |
| Stock Based Compensation To Revenue | 0.10 | 0.10 | |
| Sales General And Administrative To Revenue | 0.50 | 0.47 | |
| Research And Ddevelopement To Revenue | 0.30 | 0.28 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 19.32 | 20.28 | |
| Ebit Per Revenue | 0.13 | 0.14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.